Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

HOLX vs XRAY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HOLX Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

HOLX Overall Winner 6-Pillar Tally: HOLX 4 – 2 XRAY Matrix Metrics: HOLX 8 – 2 XRAY

As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over DENTSPLY SIRONA Inc. (XRAY) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas XRAY carries 42.5/100 (HOLD) at $8.29 (6.8x Forward P/E, 4.7% operating margin).

  • Technical & Structure Timing Caution: HOLX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 69.0); meanwhile XRAY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HOLX vs XRAY
HOLX NASDAQ Head-to-Head Winner
Hologic Inc
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$76.01
+0.48% 1D
Market Cap $16.9B
TTM Revenue $4.13B
Forward P/E 20.1x
Beta / 30D Vol 0.08β · 3% Vol
Unified Composite Score
64.2 / 100 BUY
Tech 75.0 Fund 61.0 Flow 54.0 Mom 49.2
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 69.0 · SMA20: $75.47 · SMA50: $75.29
XRAY NASDAQ
DENTSPLY SIRONA Inc.
Dental Equipment & Supplies
$8.29
-2.36% 1D
Market Cap $1.7B
TTM Revenue $3.58B
Forward P/E 6.8x
Beta / 30D Vol 0.86β · 54% Vol
Unified Composite Score
42.5 / 100 HOLD
Tech 34.0 Fund 53.0 Flow 60.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.7%), weak momentum, RSI 35
RSI-14: 35.1 · SMA20: $9.36 · SMA50: $9.21

6-Pillar Scorecard Institutional Category Breakdown (HOLX 4 – 2 XRAY)

Columns: Metric · HOLX · XRAY
1. Valuation Multiples XRAY
Forward P/E 20.1x 6.8x
Trailing P/E 31.4x 6.6x
PEG Ratio 1.66x 0.66x
EV / Revenue 4.1x 1.1x
2. Growth & Scale HOLX
Revenue Growth (YoY) +2.5% -7.5%
Earnings Growth (YoY) -9.2% +15.2%
TTM Revenue (USD) $4.13B $3.58B
Market Cap $16.9B $1.7B
3. Profitability & Quality HOLX
Gross Margin 60.4% 50.5%
Operating Margin 23.0% 4.7%
Net Profit Margin 13.2% -3.4%
Return on Equity (ROE) 10.9% -8.6%
4. Balance Sheet & Cash Flow HOLX
Cash Generation (TTM) $1.35B EBITDA $103M
Cash Flow Margin 32.7% EBITDA Mgn 2.9%
Net Cash / Leverage $23.51 Book/Sh · 10.9% ROE $2.09B Net Debt (1.69x D/E)
Dividend Yield None (0.00%) 1.88%
5. Options & Positioning HOLX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 6.3% (3rd %ile) 26.2% (<1st %ile)
Put/Call OI Skew 6.20x (Put-Skewed) 0.24x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat XRAY
OpEx & R&D Intensity 37.4% of Rev ($1.54B) 45.8% of Rev ($1.64B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HOLX (8) vs XRAY (2)
Institutional Metric HOLX XRAY Criterion Row Edge
Market Capitalization
Scale
$16.9B $1.7B Larger Scale HOLX
Trailing P/E Ratio
Valuation
31.4x 6.6x Lower Multiple XRAY
Forward P/E Ratio
Valuation
20.1x 6.8x Lower Multiple XRAY
Revenue Growth (YoY)
Growth
+2.5% -7.5% Higher Growth HOLX
Operating Margin (TTM)
Profitability
23.0% 4.7% Higher Margin HOLX
Net Profit Margin
Profitability
13.2% -3.4% Higher Margin HOLX
Return on Equity (ROE)
Capital Efficiency
10.9% -8.6% Higher ROE HOLX
52-Week Range Position
Momentum
100% ($52–$76) 2% ($8–$15) Stronger Trend HOLX
Beta / 30D Volatility
Risk Regime
0.08β · 3% Vol 0.86β · 54% Vol Lower Realized Risk HOLX
Unified Institutional Score
Composite Signal
64.2 / 100 (BUY) 42.5 / 100 (HOLD) Higher Composite HOLX
Trailing 12M Revenue (USD)
Operating Scale
$4.13B $3.58B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
60.4% 50.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.66x PEG · 4.1x EV/Rev 0.66x PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.35B EBITDA ($23.51 Book/Sh · 10.9% ROE) $103M ($2.09B Net Debt (1.69x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HOLX +13.02 pp
HOLX: +0.34% · XRAY: -12.68%
3M Horizon XRAY +1.34 pp
HOLX: +1.94% · XRAY: +3.28%
6M Horizon XRAY +13.0 pp
HOLX: +2.48% · XRAY: +15.48%
1Y Horizon XRAY +13.0 pp
HOLX: +2.48% · XRAY: +15.48%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HOLX vs XRAY. Trailing 12-month operating profitability (HOLX 23.0% vs XRAY 4.7%) and valuation multiples (HOLX 20.1x vs XRAY 6.8x Forward P/E) are benchmarked directly in Pillar 4 below.

HOLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.13B
Gross Margin60.4%
Op. Margin23.0%
ROE / Fwd P/E10.9% · 20.1x
XRAY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.58B
Gross Margin50.5%
Op. Margin4.7%
ROE / Fwd P/E-8.6% · 6.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HOLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 6.3%
IV Percentile 3rd %ile
Put/Call OI Skew 6.20x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact HOLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XRAY BREAKDOWN
77d in phase · OBV DISTRIBUTION
Current IV 26.2%
IV Percentile <1st %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact XRAY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HOLX Moat Profile Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $16.9B market capitalization and 23.0% operating margin.
OpEx & R&D Reinvestment 37.4% of Rev ($1.54B)
90D Engineering Disclosures 0 Published
XRAY Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $1.7B market capitalization and 4.7% operating margin.
OpEx & R&D Reinvestment 45.8% of Rev ($1.64B)
90D Engineering Disclosures 0 Published

Investor FAQ HOLX vs XRAY Key Questions & Quantitative Answers

As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over DENTSPLY SIRONA Inc. (XRAY) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas XRAY carries 42.5/100 (HOLD) at $8.29 (6.8x Forward P/E, 4.7% operating margin). Technical & Structure Timing Caution: HOLX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 69.0); meanwhile XRAY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HOLX leads the Growth & Scale pillar: HOLX posts +2.5% YoY revenue growth and -9.2% YoY earnings growth on $4.13B TTM revenue (60.4% gross margin, 23.0% operating margin), compared with XRAY at -7.5% YoY revenue growth and +15.2% YoY earnings growth on $3.58B TTM revenue (50.5% gross margin, 4.7% operating margin). On trailing 12-month operating scale, HOLX generates $4.13B in USD-normalized revenue versus $3.58B for XRAY. In operating R&D and SG&A reinvestment, HOLX deploys 37.4% of Rev ($1.54B) (0 90-day corporate R&D disclosures) versus 45.8% of Rev ($1.64B) (0 disclosures) for XRAY.

XRAY screens cheaper on headline valuation multiples. HOLX trades at 20.1x Forward P/E, 31.4x Trailing P/E, 1.66x PEG, and 4.1x EV/Revenue (32.7% EBITDA margin), whereas XRAY trades at 6.8x Forward P/E, 6.6x Trailing P/E, 0.66x PEG, and 1.1x EV/Revenue (2.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HOLX (10.9% ROE) versus XRAY (-8.6% ROE) capital efficiency.

In options market volatility and institutional positioning, HOLX carries 6.3% implied volatility (3rd %ile, Compressed (<25th %ile)), a 6.20x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.08β · 3% Vol realized risk). By comparison, XRAY carries 26.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.86β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.